Description
Amgevita is a biosimilar adalimumab injection available as a solution in pre-filled autoinjectors and syringes. It is indicated for the treatment of various autoimmune diseases such as rheumatoid arthritis and plaque psoriasis. As of 2025, it includes high-concentration formulations (20mg/0.2ml and 40mg/0.4ml) and is eligible for government subsidies in Singapore under the Ministry of Health (MOH) Standard Drug List.
Best for
government subsidy eligibility, rheumatoid arthritis, high-concentration formulation and standard drug list access